Back to School: How biopharma can reboot drug development. Access exclusive analysis here

ConXn: Completed Phase II/III trial enrollment

Connetics Corp. (CNCT), Palo Alto, Calif.
Product: ConXn
Business:

Read the full 93 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE